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Abstract
A prominent goal in gene therapy research concerns the development of gene transfer vehicles that can integrate
exogenous DNA at specific chromosomal loci to prevent insertional oncogenesis and provide for long-term transgene
expression. Adenovirus (Ad) vectors arguably represent the most efficient delivery systems of episomal DNA into eukaryotic
cell nuclei. The most advanced recombinant Ads lack all adenoviral genes. This renders these so-called high-capacity (hc) Ad
vectors less cytotoxic/immunogenic than those only deleted in early regions and creates space for the insertion of large/
multiple transgenes. The versatility of hcAd vectors is been increased by capsid modifications to alter their tropism and by
the incorporation into their genomes of sequences promoting chromosomal insertion of exogenous DNA. Adeno-
associated virus (AAV) can insert its genome into a specific human locus designated AAVS1. Trans- and cis-acting elements
needed for this reaction are the AAV Rep78/68 proteins and Rep78/68-binding sequences, respectively. Here, we describe
the generation, characterization and testing of fiber-modified dual hcAd/AAV hybrid vectors (dHVs) containing both these
elements. Due to the inhibitory effects of Rep78/68 on Ad-dependent DNA replication, we deployed a recombinase-
inducible gene switch to repress Rep68 synthesis during vector rescue and propagation. Flow cytometric analyses revealed
that rep68-positive dHVs can be produced similarly well as rep68-negative control vectors. Western blot experiments and
immunofluorescence microscopy analyses demonstrated transfer of recombinase-dependent rep68 genes into target cells.
Studies in HeLa cells and in the dystrophin-deficient myoblasts from a Duchenne muscular dystrophy (DMD) patient
showed that induction of Rep68 synthesis in cells transduced with fiber-modified and rep68-positive dHVs leads to
increased stable transduction levels and AAVS1-targeted integration of vector DNA. These results warrant further
investigation especially considering the paucity of vector systems allowing permanent phenotypic correction of patient-
own cell types with large DNA (e.g. recombinant full-length DMD genes).
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Introduction
Experiments in animal models of various human inherited
diseases have shown that high-capacity (hc) adenovirus (Ad)
vectors are superior to early region-deleted Ad vectors both in
terms of safety and persistence of transgene expression [1–3].
However, at present, extensive use of this gene delivery system in
in vivo settings is hampered by the difficulty in obtaining the vast
amounts of vector particles needed for large animal experiments
and the limited understanding of the physiological effects caused
by the interaction(s) between vector capsids and, for instance, the
innate immune system. In addition, because Ad genomes normally
remain episomal, hcAd vectors are of limited use in applications
aiming at stable genetic modification of dividing cell populations.
Thus, a high demand exists to endow hcAd vectors with
mechanisms that allow exogenous DNA persistence.
A strategy to achieve this goal consists of incorporating into hcAd
vector genomes the DNA integration-promoting elements from
naturally occurring integration systems such as (i) DNA transpo-
sons/transposases, (ii) retroviral long terminal repeats/integrases,
(iii) retrotransposons, (iv) DNA recombinases or (v) the Rep78/68-
binding sequences/large Rep proteins of the seemingly non-
pathogenic helper-dependent parvovirus adeno-associated virus
(AAV) [4,5]. Of these integrating hcAd-based vector systems, those
that capitalize on the DNA integration machinery of AAV have the
advantage of allowing preferential insertion of foreign DNA into the
so-called AAVS1 locus on human chromosome 19 (19q13.3-qter).
AAV trans- and cis-acting elements needed for this reaction are the
Rep78 and/or Rep68 protein and their cognate binding sequences,
respectively [6]. The cis-acting elements are located in the AAV
inverted terminal repeats (ITRs), which can fold into a palindromic
T-shaped hairpin, and in the AAV p5 promoter, which contains a
sequence dubbed the p5 integration efficiency element (p5IEE) [7].
Another shortcoming of hcAd-based gene transfer systems relates
to the fact that many clinically important cell types (e.g., human
hematopoietic stem and progenitor cells, mesenchymal stem cells
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vectors,whicharebasedonthespeciesChumanAd(hAd)serotypes
2 and 5. This is explained by the virtual absence of the Ad and
Coxsackie B virus receptor (CAR) on the surface of these cells [8–
11]. To allow efficient transduction of CAR-negative cell types,
others and we have deployed a genetic retargeting strategy whereby
cell receptor-interacting domains of the hAd serotype 5 (hAd5) fiber
are substituted by those from other Ads resulting in hcAd particles
pseudotyped with chimeric fibers [11–13].
In the present study, we describe the generation of dual hcAd/
AAV hybrid vectors (dHVs) [14] with modified capsids and with
all the AAV cis- and trans-acting elements needed for locus-specific
insertion of exogenous DNA. To avoid the well-described
interference of the large AAV Rep proteins (i.e., Rep78 and
Rep68) on the Ad-dependent DNA replication [15,16], which is
required for vector genome amplification, we devised a FLP
recombinase-dependent gene switch module to repress and
activate rep68 expression in producer and target cells, respectively.
Rep68 synthesis in target cells was induced with the aid of a fiber-
modified hcAd vector encoding a thermostable version of the
Saccharomyces cerevisae FLP recombinase (FLPe) [17,18]. Long-term
cultures and clonal analyses of human cervix carcinoma (HeLa)
cells and of myoblasts isolated from a patient with Duchenne
muscular dystrophy (DMD) were used to determine stable
transduction levels as well as the targeted chromosomal integration
frequencies of the large DNA molecules delivered by capsid-
modified and rep68-containing dHV particles. Activation of the
inducible rep68 gene contained in the dHV genome resulted in
increased stable transduction frequencies and was required for the
efficient insertion of vector sequences into the AAVS1 locus.
Moreover, Southern blot analyses of stably transduced HeLa cell
and DMD myoblast clones suggest that locus-specific vector DNA
integration occurs relatively more often in diploid than in
genetically unstable target cells. Finally, our results suggest that
linear double-stranded DNA molecules may serve as substrates for
the locus-specific AAV integration machinery.
Results
Experimental strategy
Since AAV Rep68 contains all the structural information
needed to catalyze targeted DNA insertion, we decided to focus on
the delivery into target cells of this instead of the larger Rep78
protein. However, because Ad-dependent DNA replication is
strongly inhibited by the two large Rep proteins [15,16] rep68
expression during dHV production should be minimized. Indeed,
generation of Ad-based vectors encoding Rep78 and/or Rep68 is
not a trivial matter since even relatively low concentrations of
these proteins in producer cells lead to the emergence and
selection of mutant vectors with deletions in the rep sequences [19],
and our unpublished results. Another point of concern is the
stability of Ad vector genomes containing integration modules
consisting of classic recombinant AAV (rAAV) genomes (i.e. ITR-
transgene[s]-ITR). Investigations have shown that the presence of
pairs of non-terminal inverted repeats in Ad vector genomes leads
to replication-induced recombination through these sequences
causing deletions/rearrangements in the vector DNA [20,21]. Ad
vectors containing both rAAV genomes and rep78 and/or rep68
genes may, in addition, suffer from Rep78/68-mediated rescue
(i.e. excision) of the rAAV DNA from a fraction of the vector
backbones causing transgene loss. The origin of this problem lies
in the fact that, although Rep synthesis can, to a great extent, be
inhibited by using stringent inducible gene expression systems,
most if not all of them are ‘‘leaky’’ (especially in the context of
replicating DNA templates). During the production of rep78/68-
positive Ad vectors, producer cells will thus contain not only Ad-
derived AAV helper activities (i.e. Ad gene products necessary for
AAV DNA rescue and replication [6] but also Rep78/68 proteins.
Finally, permanent expression of the rep78/68 gene at high levels is
detrimental for many cell types causing cell cycle arrest and
apoptosis [22–24].
Given all these potential pitfalls, we decided to construct hcAd-
based vectors containing rep68 genes and Rep78/68-binding
elements (RBEs) using a unique vector design in which FLP
recombinase-dependent rep68 expression units are incorporated
into the non-integrating parts of dHV genomes [14]. Previous
results have shown that Ad-dependent DNA replication in concert
with AAV ITR-mediated dimerization is the main mechanism
responsible for the generation of dHV genomes from input
monomeric templates molecularly cloned in shuttle plasmids [14].
These monomeric DNA molecules contain an Ad ITR, Ad
packaging signal and AAV p5IEE at one end and an AAV ITR at
the other end (Fig. 1A). The particular design of the resulting dHV
genomes with AAV ITR sequences at the axis of symmetry and
with the p5IEE at both extremities allows the introduction into
target cells of DNA molecules structurally resembling wild-type
AAV proviruses [25]. Resolution of the Holliday-like AAV ITR
hairpin structures at the axis of symmetry either by cellular factors
[14,26] or by Rep68-mediated nicking at the terminal resolution
site (trs; Fig. 1B) will generate monomer-sized replicative
intermediates that can be reutilized by the Ad replication
machinery to produce new dHV genomes. Because they possess
a favorable size for efficient packaging into Ad capsids (i.e.
between 27 and 38 kb) [14,27] unresolved dimeric replicative
intermediates will be preferentially packaged into Ad capsids [14]
thus giving rise to dHV particles (Fig. 1B). The localization of the
FLP-inducible rep68 gene upstream of the p5IEE in the rep68-
positive dHV genomes (Fig. 1C) should impede its Rep68-
dependent insertion into the AAVS1 locus [14]. To further reduce
the likelihood of integrating rep68 sequences into the AAVS1 locus
of target cells, the rep68 expression module was designed in such a
way that its FLPe-mediated activation is accompanied by its
physical separation from the gene(s)-of-interest. Circularization of
the FLP recombinase target (FRT)-flanked DNA by FLPe
positions a promoter in front of the rep68 open reading frame
(ORF) resulting in Rep68 synthesis. Finally, Rep68-mediated
interactions between the RBEs in the dHV genomes (i.e., AAV
p5IEE and AAV ITR) and in human chromosome 19 (i.e. AAVS1
locus) should facilitate targeted insertion of the foreign DNA
(Fig. 1C).
Construction and testing of a FLP-dependent rep68
expression unit
We started by constructing an inducible rep68 expression unit on
the basis of the FLP/FRT site-specific recombination system of
Saccharomyces cerevisiae. To this end, the coding sequence for
DsRed.T4 in pGS.pA+.DsRed [28] was replaced by that of
Rep68 giving rise to construct pGS.pA+.Rep68. The functionality
of pGS.pA+.Rep68 was tested in a transient transfection assay. This
assay consisted of introducing into pGS.pA+.Rep68-containing
PER.tTA.Cre76 cells, AAV helper functions and an rAAV vector
shuttle plasmid through infection with Ad.floxedY.F50 and
transfection of pAAV.DsRed, respectively. In the presence of
AAVhelperfunctionsplusfunctionalAAVRep68molecules,rAAV
genomes are expected to be rescued (i.e. excised) from plasmid
backbones and to originate de novo synthesized replicative interme-
diates consisting of double-stranded full-length monomeric and
dimeric vector DNA, also known as duplex monomers (DMs) and
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gene switch, we used hcAd.FLPe.F50. Negative and positive
controls consisted of pGAPDH.Rep78/68- and pAAV.DsRed-
transfected PER.tTA.Cre76 cells that were mock-infected and
infected with Ad.floxedY.F50, respectively. Results depicted in
Fig. 2 clearly show that accumulation of rAAV replicative
intermediates in the pGS.pA+.Rep68-transfected PER.tTA.Cre76
cells is strongly stimulated by infection with hcAd.FLPe.F50 (i.e. in
the presence of FLPe; compare lanes 1 and 2 of Fig. 2). In the
absence of the recombinase only low amounts of rAAV replicative
intermediates were generated (Fig. 2; lane 1). This suggests the
existence of ‘‘leaky’’ rep68 expression at a level sufficient to allow
limited amplification of rAAV DNA. Indeed, previous research has
provided evidence that only few Rep78/68 molecules are required
to induce AAV DNA replication [29]. The detection of rAAV-
specific DMs and DDs in cells that received pAAV.DsRed,
pGAPDH.Rep78/68 and Ad.floxedY.F50 (Fig. 2; lane 3) but not
incellscontaining exclusivelypAAV.DsRed andpGAPDH.Rep78/
68 (Fig. 2; lane 4) validated the assay. On the basis of these results,
we conclude that pGS.pA+.Rep68 is FLPe-responsive and gives rise
to the synthesis of functional Rep68 molecules.
Figure 1. Overview of the structure, production and applica-
tion of dHVs. (A) Diagram of dHV shuttle plasmids. The structure of
pdHV differs from that of pdHV.68/5939 and pdHV.68/3959 in that the
former construct only codes for eGFP whereas the latter plasmids have,
in addition, a FLP-inducible AAV rep68 expression module (see below)
inserted in between the Ad packaging signal and the AAV p5IEE in the
59R39 (pdHV.68/5939) or in the 39R59 orientation (pdHV.68/3959). Solid
box, Ad ITR (hAd5 base pairs 1 through 103); Y, Ad packaging signal-
containing sequence (hAd5 genome positions 104 through 454);
shaded box with broken line, inducible AAV2 rep68 expression unit;
shaded circle, p5IEE (AAV2 genome positions 153 through 291); line
with subscript ‘‘dystrophin’’, stuffer DNA derived from human
dystrophin cDNA; solid triangle, human growth hormone gene pA
signal; open box, eGFP ORF; solid box with broken arrow, hEF1a
promoter; shaded oval, AAV ITR (AAV2 nucleotides 1 through 145);
open circle, prokaryotic origin of replication. (B) Schematic represen-
tation of the rescue process of capsid-modified and rep68-positive dHV
particles. Rescue of dHV DNA into hAd5 capsids containing chimeric
fibers is initiated by releasing it from the plasmid backbone at the
indicated PmeI restriction sites and transfecting the digestion products
into the hAd5 E1-complementing PER.tTA.Cre76 cells. These cells are
next infected with the E1-deleted helper Ad vector Ad.floxedY.F50,
which supplies in trans all Ad DNA replication activities and Ad
structural proteins (including chimeric fiber proteins) needed for the
amplification and packaging of dHV DNA, respectively. Replication- and
packaging-competent tail-to-tail dimers are assembled from input
monomers due to Ad-dependent DNA replication and AAV ITR-
mediated dimerization. The resulting dHV particles display on their
surface hAd50 fiber domains and can be amplified by serial propagation
in Ad.floxedY.F50-infected producer cells prior to purification in CsCl
density gradients. The use of a helper Ad vector which has its packaging
signal flanked by bacteriophage P1 loxP sites in combination with
producer cells expressing the bacteriophage P1 cre gene strongly
inhibits the formation of helper Ad particles. (C) Transduction pathway
of rep68-positive dHVs. The FLP-inducible rep68 expression unit consists
of a direct repeat of two FRT sequences flanking the AAV2 rep68 ORF
followed by the herpes simplex virus thymidine kinase gene pA signal
and the hGAPDH promoter. Since the transcription-promoting elements
of the hGAPDH gene are positioned downstream of the Rep68-coding
sequence, the rep68 ORF is not preceded by an active promoter and
hence should not get expressed. To suppress rep68 activation by
possible cryptic promoter elements located upstream of the rep68
initiation codon, a transcriptional terminator from the murine
metallothionine gene was introduced immediately upstream of the 59
FRT site. The FLP-inducible rep68 expression module is located between
the Ad cis-acting elements (i.e., the Ad ITR and the Ad packaging signal
[Y]) and the AAV p5IEE. Excision and circularization of the FRT-flanked
DNA by FLPe will position the hGAPDH promoter in front of the rep68
ORF and lead to the synthesis of Rep68. Finally, Rep68-mediated
interactions between the RBEs in the vector DNA (i.e., AAV p5IEE and
AAV ITR) and in human chromosome 19 (i.e. AAVS1 locus) will induce
targeted chromosomal insertion of dHV DNA.
doi:10.1371/journal.pone.0003084.g001
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positive and fiber-modified dHV particles
Next, the FLP-inducible rep68 expression unit from
pGS.pA+.Rep68 was inserted in either orientation upstream of
the p5IEE in the dHV shuttle construct pAd/AAV.EGFP [14],
hereafter referred to as pdHV, to generate pdHV.68/5939 and
pdHV.68/3959, respectively (Fig. 1A). pdHV.68/5939, pdHV.68/
3959 and the rep68-negative control plasmid pdHV were digested
with PmeI and individually transfected into PER.tTA.Cre76 cells.
The PmeI digestion releases the Ad ITRs from almost the
complete plasmid backbones turning them into much more
efficient substrates for the initiation of Ad-dependent DNA
replication than undigested templates. Subsequently, helper
activities necessary for the amplification and packaging of dHV
genomes were provided in trans by the infection of producer cells
with the capsid-modified helper Ad vector Ad.floxedY.F50. After
exhibiting complete cytopathic effect, the cell cultures were
harvested and dHV seed stocks were prepared. These crude
vector preparations were used to amplify dHV particles through
four successive rounds of infection in Ad.floxedY.F50-infected
PER.tTA.Cre76 cells. Direct fluorescence microscopy revealed an
increase in the frequency of enhanced green fluorescent protein
(eGFP)-positive producer cells following each consecutive round of
vector amplification (Fig. 3A). Quantification of functional vector
particles by eGFP-directed flow cytometry showed that the
propagation kinetics of the two different rep68-positive dHVs was
very similar to that of their rep68-negative counterpart (Fig. 3B).
Both rep68-negative and rep68-positive fiber-modified dHV
particles obtained after four rounds of propagation were purified
by isopycnic CsCl density gradient ultracentrifugation, titrated and
used to transduce CD46-positive target cells that either do (HeLa
cells) or do not (DMD myoblasts) express CAR at their surface.
Direct fluorescence microcopy (Fig. 4A) and flow cytometry
(Figs. 4B and 4C) showed a clear dose-dependent increase in gene
transfer activity in both cell types. Moreover, flow cytometric
quantification of the frequency of eGFP-positive cells (Fig. 4C, left
graphs) and the average eGFP level per transduced cell (Fig. 4C,
right graphs) revealed that, for each given vector dose, dHV.F50
and dHV.68/5939.F50 gave similar transduction levels.
To investigate whether dHV.68/5939.F50 particles contain
FLP-responsive rep68-specific gene switches, we performed
Western blot analysis on lysates derived from HeLa cells
transduced with CsCl density gradient-purified dHV.F50 and
dHV.68/5939.F50 particles using a monoclonal antibody recog-
nizing all four AAV rep gene products. HeLa cells were infected
with dHV.F50 or dHV.68/5939.F50 alone (Fig. 5A; lanes 2 and 4)
or in combination with hcAd.FLPe.F50 (Fig. 5A; lanes 1 and 3).
Co-infection of the target cells with dHV.68/5939.F50 and
hcAd.FLPe.F50 resulted in robust induction of rep68 expression
(Fig. 5A; lane 3). In contrast, the amount of Rep68 produced in
dHV.68/5939.F50-infected HeLa cells in the absence of FLPe was
very low (Fig. 5A; lane 4). These results demonstrate dHV.68/
5939.F50-mediated transfer of functional rep68 gene switch
modules into target cells. Subsequently, to examine the synthesis
of Rep molecules at the single-cell level we carried out eGFP direct
fluorescence microscopy and Rep68 immunofluorescence micros-
copy on HeLa cells co-transduced with dHV.F50 and hcAd.FL-
Pe.F50 (Fig. 5B; left panels) or with dHV.68/5939.F50 and
hcAd.FLPe.F50 (Fig. 5B; right panels). The cells infected with the
rep68-negative dHV served to establish background levels for the
Rep68 immunostainings. Despite the possibility that not all target
cells were transduced simultaneously by both vector types, the
overlay of the eGFP- and Rep68-specific signals (Fig. 5B; lower
row) demonstrated co-synthesis of both proteins in most of the cells
exposed to dHV.68/5939.F50 and hcAd.FLPe.F50. As expected,
eGFP located in the cytoplasm and in the nucleus whereas Rep68
was present in the latter compartment. Moreover, generally, a
direct correlation between the strength of the eGFP- and the
Rep68-specific signals was observed.
Permanent genetic modification of HeLa cells and
myoblasts from a DMD patient by rep68-positive and
fiber-modified dHV particles
Finally, we tested the ability of dHV.68/5939.F50 to perma-
nently transduce target cells by locus-specific transgene integration
using two different human cell types, i.e., HeLa cells and DMD
myoblasts. HeLa cells were chosen for this purpose because they
constitute a reference cell line on which both wild-type AAV and
Rep78/68-dependent DNA integration have been evaluated both
in terms of stable transduction levels and targeted DNA insertion
proficiencies. Myoblasts are being deployed in clinical trials for
more than a decade to develop an allogeneic cell therapy for
DMD [30]. One of the problems associated with this treatment
modality is that it depends on strong and durable immunosup-
Figure 2. Testing the functionality of pGS.pA+.Rep68 and
hcAd.FLPe.F50. Extrachromosomal DNA was extracted from PER.
tTA.Cre76 cells co-transfected with the rAAV vector shuttle plasmid
pAAV.DsRed and the FLP-activatable rep68 expression plasmid
pGS.pA+.Rep68 and infected 24 h later with Ad.floxedY.F50 alone
(lane 1) or with Ad.floxedY.F50 plus hcAd.FLPe.F50 (lane 2). Positive
(lane 3) and negative (lane 4) controls consisted of extrachromosomal
DNA extracted from Ad.floxedY.F50- and mock-infected PER.tTA.Cre76
cells, respectively, co-transfected with pAAV.DsRed and the constitutive
rep78/68 expression plasmid pGAPDH.Rep78/68. The extracts were
treated with DpnI to selectively digest input, non-replicated, prokary-
otic DNA and were subjected to Southern blot analysis using a probe
corresponding to the DsRed.T4 ORF. Lane M, GeneRuler DNA Ladder Mix
molecular weight marker (Fermentas). The positions and sizes (in kb) of
the rAAV replicative intermediates (i.e., DMs and DDs) are indicated. The
numerals at the left correspond to restriction DNA fragment sizes in kb.
doi:10.1371/journal.pone.0003084.g002
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autologous myoblasts may obviate the need to severely immuno-
suppress the patients. We previously showed that dystrophin-
defective myoblasts are very well transduced ex vivo by non-
integrating hcAd-based vectors carrying the receptor-interacting
domains of hAd serotype 50 (hAd50) fibers [11]. This makes it
relevant to test the ability of dHV.68/5939.F50 to stably transduce
DMD myoblasts through targeted transgene integration. More-
over, contrary to HeLa cells, the DMD myoblasts used in this
study possess a normal, diploid karyotype [31].
HeLa cells and DMD myoblasts were independently exposed to
equal doses of dHV.F50 or dHV.68/5939.F50, either alone or
together with a constant amount of hcAd.FLPe.F50. Three days
later the initial levels of target cell transduction were determined
by eGFP-directed flow cytometry. The frequencies of eGFP-
positive cells were within a relatively narrow range, i.e., between
72 and 78% for the HeLa cells and between 76 and 81% for the
DMD myoblasts. Next, the stable transduction frequencies (STFs)
reached by dHV.F50 and by dHV.68/5939.F50 were determined
by extensively subculturing both types of dividing cells and by
measuring the percentages of eGFP-positive cells through flow
cytometry as a function of time. This experimental setup does not
introduce any bias towards the selection of cells carrying
chromosomally integrated vector DNA and prevents that cells
containing only episomal vector genomes are included in the STF
calculations, which is a concern given the relatively long half-life of
eGFP [32]. Stable transduction levels were reached at 27 days
postinfection in HeLa cells whereas it took 56 days before the
percentage of eGFP-positive DMD myoblasts stabilized, most
likely reflecting the lower division rate of the latter cell type. The
STFs obtained with dHV.68/5939.F50 in the presence of
hcAd.FLPe.F50 were 0.6% (n=2) and 0.4% (n=1) for HeLa cells
and DMD myoblasts, respectively (n events acquired=10,000). In
the absence of FLPe, dHV.68/5939.F50 yielded an STF of 0.05%
(n=2) for HeLa cells and of 0.1% (n=1) for DMD myoblasts (n
events acquired=10,000). Thus, rep68 gene activation increased
by 12- and 4-fold the STF of dHV.68/5939.F50-transduced HeLa
cells and DMD myoblasts, respectively. Importantly, infection of
both target cell types with the control vector dHV.F50 alone or
together with hcAd.FLPe.F50 gave rise to similar STFs as
observed for HeLa cells and DMD myoblasts transduced
exclusively with dHV.68/5939.F50.
To determine the frequencies of targeted DNA integration,
stably transduced HeLa cells and DMD myoblasts were isolated
from cell cultures initially exposed to both dHV.68/5939.F50 and
hcAd.FLPe.F50 and individually expanded. HeLa cell clones
derived from cultures infected exclusively with dHV.68/5939.F50
served as controls. Genomic DNA was extracted from the various
cell lines and subjected to Eco32I digestion and Southern blot
analysis. The transferred DNA was incubated first with an AAVS1-
Figure 3. Propagation of rep68-positive and fiber-modified dHVs. (A) Direct fluorescence microscopy analysis of the PER.tTA.Cre76 cells used
for the serial propagation of dHV.F50, dHV.68/5939.F50 and dHV.68/3959.F50. (B) Flow cytometric analysis of HeLa cells employed for the
determination of the eGFP transfer activity of clarified producer cell lysates derived from consecutive rounds of vector amplification. P1, passage 1; P2,
passage 2; P3, passage 3; P4, passage 4.
doi:10.1371/journal.pone.0003084.g003
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PLoS ONE | www.plosone.org 5 August 2008 | Volume 3 | Issue 8 | e3084Figure 4. Transduction of target cells by CsCl density gradient-purified dHV.F50 and dHV.68/5939.F50 particles. (A) Direct fluorescence
microscopy analysis of HeLa cells and DMD myoblasts that were either mock-infected or infected with 4, 20 or 100 HTUs of dHV.F50 or dHV.68/
5939.F50 per cell. (B) Representative flow cytometry histograms corresponding to HeLa cells and DMD myoblasts transduced with different amounts
of dHV.F50 or dHV.68/5939.F50 (i.e. 0, 4, 20 or 100 HTUs/cell). The % of maximum refers to the ratio between the number of events analyzed in each
case and the number of events in the sample with the largest number of events. (C) Quantification by flow cytometry of gene transfer into HeLa cells
and DMD myoblasts exposed to 4, 20 or 100 HTUs of dHV.F50 or dHV.68/5939.F50 per cell (n=3). Gene transfer activity is expressed both in terms of
the frequency of eGFP-positive cells and the mean fluorescent intensity (MFI) of the transduced cells (which reflects mean intracellular eGFP levels).
Error bars represent standard deviations. All measurements were performed at 72 hours postinfection.
doi:10.1371/journal.pone.0003084.g004
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stripping, was exposed to a mixture of two probes binding
immediately downstream of the rep68 gene and close to the right
end of the monomeric vector genome (Fig. 6A; lower panel).
Examples of autoradiograms derived from these experiments are
shown in Fig. 6B (HeLa cell clones) and Fig. 6C (DMD myoblast
clones). Hybridization of a particular Eco32I fragment with both
the AAVS1- and dHV.68/5939.F50-specific probes signifies inser-
tion of vector DNA into the AAVS1 locus on human chromosome
19 (Figs. 6B and 6C, open arrowheads). Subsequently, the
membrane was once again stripped and incubated with a probe
specific for a 1.9-kb Eco32I fragment in the vector genome
(Fig. 6A; lower panel). The autoradiograms corresponding to
hybridizations using the AAVS1-specific probe showed that 50% of
the 38 randomly selected HeLa cell clones yielded DNA fragments
with larger and, less often, smaller sizes than that of the 5.6-kb
Eco32I fragment characteristic for undisrupted AAVS1 alleles
(Fig. 6B; upper panel and Table 1). This observation is consistent
with the well-known capacity of Rep78 and/or Rep68 to locally
amplify the AAVS1 region due to the usage of its RBE and trs as an
origin of replication [33]. Thus, the absence of detectable changes
to the AAVS1 loci in the other 50% of the HeLa cell clones most
likely reflects the presence of no or few Rep68 molecules in their
founder cells probably due to a lack of FLPe. In agreement with
this interpretation, no disruptions of the AAVS1 alleles were found
after Southern blot analysis of chromosomal DNA extracted from
40 randomly selected clones of HeLa cells exposed exclusively to
dHV.68/5939.F50 (Fig. 6D; Table 1), indicating that although
‘‘leaky’’ rep68 expression may occur (Fig. 5A) in most cases the
amount of Rep68 does not suffice to amplify the AAVS1 region.
Consistent with this finding, Southern blot hybridization using the
vector-specific probes revealed that these clones did not have
dHV.68/5939.F50 DNA integrated into the AAVS1 region (data
not shown). Conversely, in the presence of the FLPe-encoding
hcAd vector, integration of dHV.68/5939.F50 DNA into the
AAVS1 locus could be demonstrated (Fig. 6B; middle panel and
Table 1). The targeted DNA integration efficiency, as determined
on the basis of the total number of HeLa cell clones analyzed was
24% (9/38), whereas if one considers exclusively clones with
discernible changes in the AAVS1 locus (as a surrogate indicator for
cells that originally contained enough Rep68) it reached 47% (9/
19; Fig. 6B; Table 1). The same analysis applied to autoradio-
grams corresponding to DMD myoblast clones revealed that these
cells were targeted at the AAVS1 locus with an efficient of 28% (5/
18) or 100% (5/5; Fig. 6C; Table 1), respectively.
Molecular characterization of AAVS1-foreign DNA
junctions following dHV.68/5939.F50-mediated gene
transfer
To confirm by an independent method the ability of rep68-
positive dHV particles to accomplish locus-specific foreign DNA
insertion, we performed experiments aiming at the isolation of
junctions between AAVS1 and vector DNA. To this end, DMD
myoblasts were transduced with dHV.68/5939.F50 alone or
together with hcAd.FLPe.F50. Subsequently, chromosomal DNA
was extracted from the transduced cells and AAVS1-vector DNA
junctions were analyzed by PCR (Fig. 7A). Chromosomal DNA
derived from human cells stably transduced by dHV.68/5939.F50
DNA in a non-targeted (i.e. HeLa cell clone N+2) and AAVS1-
specific (i.e. DMD myoblast clone 3C5) manner served as negative
and positive controls, respectively. The DNA derived from the
DMD myoblast clone yielded a discrete PCR fragment whereas no
amplification product was obtained with the DNA from the HeLa
cell clone (Fig. 7B, lower panel, compare lanes 1 and 2). Nested
PCR products were also detected in samples corresponding to
reactions performed on DNA from DMD myoblast cultures
transduced with dHV.68/5939.F50 alone (Fig. 7B, lower panel,
lane 3) or together with hcAd.FLPe.F50 (Fig. 7B, lower panel, lane
4). Importantly, however, a much broader range of PCR product
sizes was present in the sample derived from the cells that had
been exposed to both vectors (Fig. 7B, lower panel, compare lanes
3 and 4). These results indicate dHV.68/5939.F50 DNA
Figure 5. Testing the inducible rep68 expression unit in
dHV.68/5939.F50 particles purified by CsCl density gradient
ultracentrifugation. (A) Western blot analysis of FLPe-induced Rep68
synthesis. HeLa cells were co-transduced with dHV.F50 and hcAd.
FLPe.F50 (lane 1) or with dHV.68/5939.F50 and hcAd.FLPe.F50 (lane 3) or
were transduced exclusively with dHV.F50 (lane 2) or with dHV.68/
5939.F50 (lane 4). Three days postinfection, cellular proteins were
extracted, separated in an SDS-10% polyacrylamide gel and transferred
to a polyvinylidene fluoride membrane. Next, the membrane was
incubated with a monoclonal antibody specific for all four AAV rep gene
products. An antibody directed against actin served as a loading
control. (B) eGFP direct fluorescence microscopy and Rep68 immuno-
fluorescence microscopy on HeLa cells infected with hcAd.FLPe.F50
(50 GSAUs/cell) and either dHV.F50 (5 HTUs/cell; left column) or
dHV.68/5939.F50 (5 HTUs/cell; right column). The pictures are derived
from representative microscopic fields. The fluorescent signals derived
from the green and red channels are overlaid in the lower panels. The
arrowheads in the right panels point to cells containing both eGFP and
Rep68. Note that the former protein is distributed throughout the cell
whereas the latter is confined to the nucleus. Original magnification:
4006.
doi:10.1371/journal.pone.0003084.g005
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PLoS ONE | www.plosone.org 7 August 2008 | Volume 3 | Issue 8 | e3084Figure 6. Examination of targeted versus random dHV.68/5939.F50 DNA insertion through Southern blot analysis of genomic DNA.
(A) Upper panel, Eco32I restriction map of the AAV DNA preintegration region (i.e. the AAVS1 locus) on human chromosome 19 at 19q13.3-qter.
Vertical line and solid oval, trs and RBE, respectively. The vertical solid arrows indicate Eco32I recognition sites delimiting a 5.6-kb DNA segment. The
solid horizontal bar denotes the AAVS1-specific probe drawn in relation to its target sequence (diagram not on scale). Lower panel, Eco32I restriction
map of dHV.68/5939.F50 DNA showing the various hybridization probes (horizontal solid bars) drawn in relation to their cognate target sequences
(drawing not on scale). For an explanation of symbols and abbreviations, see the legend of Fig. 1. (B) Ten micrograms of total cellular DNA from 10
representative clones derived from HeLa cells co-infected with dHV.68/5939.F50 and hcAd.FLPe.F50 were digested with Eco32I. Following agarose gel
electrophoresis, the resolved DNA fragments were subjected to Southern blot analysis with the AAVS1-specific probe (AAVS1 probe; upper panel).
After removal of the AAVS1-specific probe, the transferred DNA was incubated simultaneously with a probe derived from the AAV p5IEE plus the rbG
gene pA signal and a probe specific for the eGFP ORF (59 and 39 vector probes; middle panel). Finally, following a second stripping step, the
transferred DNA was exposed to a fourth probe corresponding to the 1.9-kb Eco32I fragment in the dHV.68/5939.F50 genome (internal vector probe;
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blot data (Fig. 6 and Table 1), show that targeted integration
events are more frequent in cells in which rep68 expression is up-
regulated by FLPe than in cells in which the rep68 gene switch is
not activated. AAV Rep78/68-dependent DNA integration into
the AAVS1 locus is not site-specific in the strict sense since it does
not take place at a single nucleotide position but within a relatively
long stretch of DNA. As a result, AAVS1-exogenous DNA
junctions generated through the AAV machinery are usually
present as single copies within a population of stably transduced
cells. Thus, the smear detected in Fig. 7B, lane 4 most likely
reflects the amplification of a mixture of AAVS1-dHV.68.5939.F50
DNA junctions with various sizes as observed following wild-type
AAV DNA integration. To investigate this, PCR products from
the smear (Fig. 7B, lane 4) were inserted into the cloning vector
pCR-Blunt II-TOPO. The PCR fragment corresponding to the
DMD myoblast clone 3C5 (Fig. 7B, lane 2) was cloned in parallel.
Plasmid DNA purified from randomly selected colonies was
digested with EcoRI to release the inserts. As expected, agarose gel
electrophoresis revealed differently sized inserts reflecting the
variation in vector DNA insertion sites within the AAVS1 locus
(data not shown). Finally, DNA sequencing of these inserts
representing individual integration events revealed the precise
nucleotide location at which target site and vector DNA covalently
joined each other. Two examples are depicted in Fig. 7C.
Altogether, these experiments complement the Southern blot data
presented in Fig. 6 and firmly establish the capacity of rep68-
positive dHV particles to accomplish insertion of large DNA at a
specific locus in the human genome.
Discussion
The ability of wild-type AAV to insert its DNA into a specific
genomic region in cultured cells of higher primates is unique
among all known eukaryotic viruses. However, the AAV DNA
integration mechanism remains sketchy, partially owing to its
complexity [34]. For example, it is not known whether the pre-
integration complexes consist of DNA molecules with linear,
circular or both types of topologies. There is evidence, nonetheless,
for genomic insertion through circular intermediates from studies
showing (i) the capacity of rAAV plasmids to integrate into the
AAVS1 locus, (ii) the generation of circular double-stranded DNA
via AAV ITR-mediated intermolecular recombination and (iii) the
presence in cells latently infected with wild-type AAV of head-to-
tail proviral tandem repeats [34]. The unique structure of dHV
genomes consisting of linear DNA molecules that lack AAV ITRs
at one or both ends in their monomeric and dimeric configuration,
respectively, precludes the generation of circular integration
substrates via AAV ITR-mediated recombination. Our finding
that Rep68 can catalyze the insertion of dHV DNA into the
AAVS1 region thus suggests that linear templates are also amenable
to the AAV Rep78/68-dependent integration process.
Although detailed knowledge about the AAV DNA integration
mechanism is lacking, researchers are actively pursuing the
development of gene delivery systems that exploit the desirable
feature of locus-specific integration provided by AAV elements
[4,5,35,36]. When compared to non-targeted integrating vectors,
these gene transfer systems might impose a lower risk of insertional
oncogenesis caused by the inactivation of tumour suppressor genes
or, as observed in clinical trials using gammaretroviral vectors, by
the dysregulation of proto-oncogenes [37]. Among the many viral
and non-viral vector systems capitalizing on the AAV integration
machinery are those based on hcAd vectors [14,38,39]. Recchia
and colleagues incorporated rAAV DNA encoding GFP and
hygromycin B phosphotransferase into an hcAd vector genome
[38]. Co-infection of Hep3B cells with the resulting vector and
another hcAd vector containing a bacteriophage T7 promoter-
driven rep78 gene at a multiplicity of infection (MOI) of 10
transducing units per cell each followed by hygromycin B selection
revealed that the overall STF was 0.4% (i.e. 400 hygromycin B-
resistant clones/10
5 target cells). According to the authors, similar
results were obtained in other human hepatic cell lines [38]. Of
note, the STF was not enhanced by AAV rep78 expression.
However, Rep proteins did promote the insertion of the AAV
Table 1. Frequencies of targeted foreign DNA integration events derived from Southern blot analysis of dHV.68/5939.F50-
transduced HeLa cell and DMD myoblast clones.
HeLa cells DMD myoblasts
dHV.68/5939.F502
hcAd.FLPe.F50
dHV.68/5939.F50+
hcAd.FLPe.F50
dHV.68/5939.F50+
hcAd.FLPe.F50
Randomly selected eGFP
+ clones (N) 40 38 18
Clones with AAVS1 disruptions (D)/N [%] 0/40 [0] 19/38 [50] 5/18 [28]
Targeted integration events/N [%] 0/40 [0] 9/38 [24] 5/18 [28]
Targeted integration events/D [%] 0/0 [0] 9/19 [47] 5/5 [100]
doi:10.1371/journal.pone.0003084.t001
lower panel). Clones derived from HeLa cells with AAV Rep68-induced disruptions in the AAVS1 locus are indicated by solid arrows, whereas those
that also have dHV.68/5939.F50 DNA inserted into this specific region of human chromosome 19 are discriminated by open arrows. Marker, GeneRuler
DNA Ladder Mix molecular weight marker. (C) Ten micrograms of total cellular DNA from 10 clones of DMD myoblasts co-infected with dHV.68/
5939.F50 and hcAd.FLPe.F50 were digested with Eco32I. Following agarose gel electrophoresis, the resolved DNA species were subjected to Southern
blot analysis with the AAVS1-specific probe (AAVS1 probe; upper panel) and, after its removal, with the two probes binding close to the termini of the
dHV.68/5939.F50 genome (59 and 39 vector-specific probes; lower panel). Clones derived from DMD myoblasts with AAV Rep68-induced disruptions in
the AAVS1 locus are indicated by solid arrows, whereas those that also have dHV.68/5939.F50 DNA inserted into this specific region of human
chromosome 19 are discriminated by open arrows. Marker, GeneRuler DNA Ladder Mix molecular weight marker. (D) Ten micrograms of total cellular
DNA from 9 representative clones derived from HeLa cells infected with dHV.68/5939.F50 alone were digested with Eco32I. Following agarose gel
electrophoresis, the resolved DNA fragments were subjected to Southern blot analysis with the AAVS1-specific probe. Marker, GeneRuler DNA Ladder
Mix molecular weight marker.
doi:10.1371/journal.pone.0003084.g006
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of stably transduced HepG2 cells [38]. Similar results were
obtained with a single-particle version of this hcAd/AAV hybrid
vector system accommodating a 3.8-kb rAAV genome and an
inducible rep78 expression unit regulated by a doxycycline-
controlled transcriptional silencer [40]. Recently, Wang and
Lieber generated capsid-modified hcAd vectors containing a
GFP-encoding rAAV genome significantly larger than those tested
by Recchia and co-workers [39]. In parallel, they succeeded in
rescuing and propagating a Rep78-encoding hcAd vector by
relying on a strategy based again on a transcriptional regulatory
element with low basal activity in producer cells (i.e. the human b-
globin locus control region). Co-infection of human megakaryo-
blastic leukemia (Mo7e) cells with the rAAV- and rep78-containing
hcAd vectors at an MOI of 300 and 800 genomes per cell,
respectively, followed by their clonal expansion yielded 25.8% cell
Figure 7. Integration of exogenous DNA into AAVS1 after gene transfer with rep68-positive dHV.68/5939.F50 particles. (A) Overview of
the PCR-based targeted DNA integration assay. Genomic DNA extracted from HeLa cell clone N+2 and DMD myoblast clone 3C5 served as control
templates derived from cells genetically modified through vector DNA insertion outside and inside the AAVS1 locus, respectively. The experimental
samples consisted of chromosomal DNA from DMD myoblasts infected with dHV.68/5939.F50 alone (40 HTUs/cell) or co-infected with dHV.68/
5939.F50 (40 HTUs/cell) and hcAd.FLPe.F50 (40 GSAUs/cell). The upper part of the boxed pictogram represents the section of human chromosome 19
at 19q13.3-qter harboring the AAVS1 locus. Vertical line and adjacent oval, trs and RBE, respectively; horizontal fading bar, AAV DNA preintegration
region; green box, representation of a targeted vector DNA insertion event leading to an AAVS1-foreign DNA junction; numbered black and green
arrows symbolize AAVS1- and vector DNA-specific primers, respectively. (B) Agarose gel electrophoresis of PCR products resulting from amplifications
carried out on chromosomal DNA from HeLa cell clone N+2 (lanes 1), DMD myoblast clone 3C5 (lanes 2), DMD myoblast population transduced with
dHV.68/5939.F50 alone (lanes 3) and DMD myoblast population co-transduced with dHV.68/5939.F50 and hcAd.FLPe.F50 (lanes 4). Lanes M, Gene Ruler
DNA Ladder Mix molecular weight marker. Upper panel, internal control PCR products resulting from amplifications performed with the AAVS1-
specific primers # 211 and # 196. Lower panel, nested PCR products of amplifications carried out with oligodeoxyribonucleotides # 212 and # 188
on DNA synthesized with the aid of primers # 211 and # 651. (C) Nucleotide sequence analysis of junctions generated between AAVS1 and
exogenous DNA following co-transduction of DMD myoblasts with dHV.68/5939.F50 and hcAd.FLPe.F50. The DNA sequencing data in the upper and
lower panel correspond to inserts derived from PCR amplifications on chromosomal DNA from myoblast clone 3C5 and from the DMD myoblast
population co-transduced with dHV.68/5939.F50, respectively. The black and green bars indicate AAVS1 and vector DNA, respectively. Vertical arrows
points to the junction between AAVS1 and dHV.68/5939.F50 DNA present in each individual clone.
doi:10.1371/journal.pone.0003084.g007
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percentage of GFP-positive cells in individual Mo7e clones varied
greatly, which makes it very hard to accurately determine the
actual STF. Nonetheless, from data presented in Fig. 9 of the study
by Wang and Lieber [39] one can deduce that the STF at best was
in the order of a few percent. Substitution of the rep78-positive for
a rep78-negative hcAd vector resulted in somewhat lower stable
transduction levels [39]. Finally, in 30% of the stably transduced
clones derived from Mo7e cells co-infected with the rAAV- and
rep78-containing hcAd vectors, the foreign DNA was found to be
inserted into the AAVS1 region [39].
In this study, we report the generation of tropism-modified
dHVs containing AAV rep68 expression units and show their
ability to mediate integration of DNA fragments of at least 10.3 kb
into the AAVS1 locus on human chromosome 19 in HeLa and
muscle progenitor cells. Side-by-side rescue and propagation
experiments revealed that the growth properties of the rep68-
positive dHVs are very similar to that of the rep68-negative control
vector. These results signify that the amounts of Rep68 made
during the rescue and propagation of the rep68-positive dHVs were
not enough to markedly inhibit their production. Transduction of
rapidly proliferating human cells with dHV.68/5939.F50 particles
followed by the activation of the rep68 gene switch incorporated in
the vector genome led to the insertion at 19q13.3-qter of large
DNA molecules that included a functional transgene expression
unit and human dystrophin-coding sequences. Significantly, in
HeLa cells exposed exclusively to dHV.68/5939.F50 (i.e. hcAd.
FLPe.F50-negative cells), the basal Rep68 levels did not suffice to
disrupt AAVS1 loci and, in agreement with this observation, no
targeted DNA insertion could be detected in any of the 40 clones
that were analyzed (Fig. 6). However, by using a more sensitive
PCR-based assay, evidence for low-level AAVS1-targeted vector
DNA insertion in FLPe-negative cells was found (Fig. 7B, lane 3).
An interesting aspect of the present study is the side-by-side
comparison of the performance of an AAV Rep78/68-dependent
DNA targeting system in cell types with very different genetic
stabilities. HeLa cells are notorious for their aneuploidy and
widespread translocations, whereas the human myoblasts used in
this study remain diploid even after many cell divisions [31]. If one
considers only those cells in which Rep68 induced unambiguous
AAVS1 disruptions, the targeted DNA insertion efficiency reached
47% in HeLa cells (9/19 clones) and a remarkable 100% in DMD
myoblasts (5/5 clones). It is thus tempting to speculate that the
lower targeted DNA integration proficiency of hybrid vector
genomes in HeLa cells is a consequence of the higher genetic
instability of these tumor cells causing a substantial fraction of
vector genomes to insert randomly at double-stranded breaks
possibly through non-homologous end-joining as observed with
rep-negative rAAV DNA [41]. This would suggest that in the
presence of appropriate amounts of Rep78 and/or Rep68
molecules, dHV DNA might indeed display a marked preference
for locus-specific insertion in the genomes of therapeutically
relevant (i.e. non-transformed) cell types. Further experiments that
might include tests on a larger panel of cell types are warranted to
establish or disprove this postulate.
Importantly, we demonstrated that transduction of human cells
with capsid-modified dHV particles can lead to long-term
transgene expression in an AAV Rep68-dependent manner.
However, notwithstanding the diverse experimental setups used,
a common feature of this and other Rep78/68-dependent
integrating hcAd vector-based gene carriers is their overall low
STFs. The low STFs reached by these hybrid vector systems are at
odds with those reported for wild-type AAV in human cells in
culture. For instance, using Southern blot analyses, Hamilton and
colleagues deduced that wild-type AAV can stably transduce up to
50% of infected HeLa cells [42]. In addition, by deploying a
quantitative real-time PCR assay, other investigators showed that
wild-type AAV DNA integrates at 19q13.3-qter in at least 15% of
infected HeLa cells [43,44]. Recchia and colleagues found for their
monopartite hcAd/AAV hybrid vector system that the efficiency
of AAVS1-specific integration was directly proportional to the
Rep78 level in the target cells [40]. However, as mentioned
previously, above a certain concentration, which might be
different for different cell types, the two largest AAV Rep proteins
have cytostatic or even cytotoxic properties. The low STFs
achieved by the Rep78/68-dependent integrating hcAd vectors in
long-term experiments deploying rapidly proliferating cells may
thus relate to uncontrolled Rep78/68 synthesis. According to this
hypothesis, many of the cells that have vector DNA integrated into
the AAVS1 locus will display a strong growth disadvantage due to
(persistent) high Rep78/68 levels. This will result in the selection of
cells that contain no or few Rep78/68 molecules and are therefore
not stably transduced or have the vector DNA integrated outside
of the AAVS1 region.
The idea of a strong selection against cells displaying high
Rep68 activity is consistent with the observation that although
most cells that initially received dHV.68/5939.F50 were also
transduced by hcAd.FLPe.F50, a significant proportion of the
randomly isolated HeLa cell and DMD myoblast clones did not
show evidence of Rep68-induced AAVS1 disruptions (i.e., 50 and
72%, respectively). Future hcAd/AAV hybrid vector systems
should therefore be designed in such a way as to ensure that the
Rep78/68 activity is minimal in producer cells and high but short-
lived in target cells. Inducible gene expression cassettes encoding
Rep78 and/or Rep68 variants whose stability or subcellular
localization can be controlled by cell-permeable small-molecule
drugs may help to fulfill these requirements. Such controllable
gene expression may, in addition, allow the production of rep68-
positive dHV particles that are not dependent on the introduction
of FLPe or on any other foreign protein into target cells.
Materials and Methods
Cells
Culturing conditions for the human cervical carcinoma (HeLa)
cells (American Type Culture Collection), the hAd5 early region 1
(E1)-deleted and bacteriophage P1 cre-expressing PER.tTA.Cre76
cells and the DMD myoblasts have been described elsewhere
[11,31,45].
DNA constructions
Recombinant DNA techniques were performed by using
established methods [46] or following the instructions supplied
with specific reagents. Large-scale plasmid DNA purifications were
carried out using JetStar 2.0 kits (Genomed) according to the
manufacturer’s recommendations. All DNA constructs as well as
their nucleotide sequences are available upon request.
Viral vectors
The production and titration of stocks of the E1-deleted and
capsid-modified helper Ad vector Ad.floxedY.F50 have been
previously described [11]. Ad.floxedY.F50 particles display at
their surface chimeric fiber proteins consisting of basal shaft
sequences from hAd5 and apical shaft and knob domains from
hAd50 [11]. The rescue and propagation of dHV.F50, dHV.68/
3959.F50 and dHV.68/5939.F50 were carried out essentially as
described elsewhere [11,14]. The titers of dHV.F50, dHV.68/
3959.F50 and dHV.68/5939.F50 stocks were determined by flow
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expressed as HeLa-cell transducing units (HTUs) per ml. The
fiber-modified hcAd vector hcAd.FLPe.F50 served as source of
FLPe [17]. hcAd.FLPe.F50 particles were produced in PER.
tTA.Cre76 cells using the hcAd vector shuttle plasmid pAd.
FLPe.dAgeI together with Ad.floxedY.F50. pAd.FLPe.dAgeI was
derived from construct pAdFLPe [18] by removal of a 3.3-kb AgeI
fragment comprising stuffer sequences derived from the human
hypoxanthine guanine phosphoribosyltransferase 1 gene. As a consequence,
the FLPe-encoding hcAd.FLPe.F50 vector particles contain a
27.4-kb genome. Titration of the hcAd.FLPe.F50 preparation was
performed on HeLa cells containing the FLP-responsive construct
pGS.pA+.DsRed [28]. Induction of the synthesis of the fluorescent
reporter protein DsRed.T4 was determined through flow
cytometry and the corresponding functional titers were expressed
as gene switch-activating units (GSAUs) per ml.
Flow cytometry
Quantification of eGFP- or DsRed.T4-positive cells was carried
out by using a BD LSR II flow cytometer (Becton Dickinson). In
all instances, 10,000 events were acquired. Data was analysed with
the aid of BD FACSDiva Software version 5.0.1 (Becton
Dickinson).
DNA transfections
Plasmid DNA transfections were carried out with Lipofectamine
(Invitrogen) as specified before [14].
AAV-dependent DNA replication assay
The functionality of the FLP-activatable AAV serotype 2
(AAV2) rep68 expression plasmid pGS.pA+.Rep68 and of
hcAd.FLPe.F50 were evaluated as follows. PER.tTA.Cre76 cells
were seeded in 6-well plates (Greiner) at a density of 2.5610
6 cells
per well. The next day, these cells were transfected with 1.5 mgo f
pGS.pA+.Rep68 and 1.5 mg of the rAAV vector shuttle construct
pAAV.DsRed. pAAV.DsRed contains an expression unit consist-
ing of a chimeric human elongation factor 1a (hEF1a) gene promoter
[47], the DsRed.T4 ORF and the rabbit b-globin (rbG) gene
polyadenylation (pA) signal. The following day, the transfected
cells were co-infected with Ad.floxedY.F50 (5 infectious units
[IUs]/cell) and hcAd.FLPe.F50 (50 GSAUs/cell). PER.tTA.Cre76
cells transfected with 1.5 mg of pAAV.DsRed and 1.5 mg of the
AAV2 rep78/68 expression plasmid pGAPDH.Rep78/68 and
infected with Ad.floxedY.F50 at an MOI of 5 IUs per cell served
as positive control. pGAPDH.Rep78/68 directs the constitutive
synthesis of Rep78 and Rep68 from the promoter of the human
glyceraldehyde-3-phosphate dehydrogenase (hGAPDH) gene [14]. Nega-
tive controls consisted of pGS.pA+.Rep68- and pAAV.DsRed-
transfected PER.tTA.Cre76 cells infected with Ad.floxedY.F50
alone and of pGAPDH.Rep78/68- and pAAV.DsRed-transfected
PER.tTA.Cre76 cells that were not exposed to hcAd.FLPe.F50 or
Ad.floxedY.F50. Three days posttransfection, the cells were
harvested and processed for extrachromosomal DNA extraction.
Extrachromosomal DNA extraction and analysis
The purification of extrachromosomal DNA was performed as
previously described [48]. To selectively degrade the prokaryotic
input DNA, the samples were treated for 1 h at 37uC with DpnI.
After agarose gel electrophoresis through 1% agarose gels in 16
Tris-acetate-EDTA buffer, the DNA was transferred by capillary
action onto nylon membranes (Amersham Hybond-XL; GE
Healthcare). These membranes were subsequently incubated with
blocking solution, exposed to the DNA probe specified below and
repeatedly washed using a standard Southern hybridization
procedure. Finally, the Southern blots were exposed to autoradi-
ography films (Amersham Hyperfilm MP; GE Healthcare).
rAAV-specific replication products were detected with the aid of
the 0.7-kb NcoI6Eco52I fragment from pAAV.DsRed, which
includes the entire DsRed.T4 ORF. This DNA probe was labeled
with [a-
32P]dATP (GE Healthcare) by using the HexaLabel DNA
Labeling Kit (Fermentas).
Transduction experiments
HeLa cells and DMD myoblasts were seeded at densities of
1.0610
5 and 4.0610
5 cells per well of 24-well plates (Greiner),
respectively. After an overnight incubation period the cells were
exposed for 24 hours to dHV.50 and dHV.68/5939.F50 at 4, 20
and 100 HTUs/cell in a total volume of 500 ml. Direct
fluorescence microscopy and eGFP-directed flow cytometry were
carried out 72 hours postinfection. Mock-infected HeLa cells and
DMD myoblasts processed in parallel served to set the background
levels of each assay.
Light microscopy and immunostaining
eGFP direct fluorescence microscopy and AAV Rep immuno-
fluorescence microscopy were performed with an Olympus IX51
inverse fluorescence microscope. Images were captured by a
ColorView II Peltier-cooled charge-coupled device camera and
were archived using analySIS software (Soft Imaging Systems).
Cells were processed for immunostaining as described before [11]
except that the primary antibody solution consisted of a 1:50
dilution of murine monoclonal antibody 303.9 (PROGEN
Biotechnik; catalog number: 61069), which recognizes all four
AAV Rep proteins.
Western blot analysis
Two-cm
2 monolayers of HeLa cells were washed once with
phosphate-buffered saline and dissolved in 100 ml ice-cold lysis
buffer consisting of 20 mM Tris-HCl (pH 7.6), 150 mM NaCl,
0.1% sodium dodecyl sulfate (SDS), 0.5% sodium deoxycholate,
1% Nonidet P40 and 10% glycerol plus a cocktail of protease
inhibitors (Complete Mini, Roche Applied Science). The protein
lysates were spun for 10 min at 4uC in a minicentrifuge at
25,0006 g. Fifteen ml of the resulting supernatants were mixed
with 3 mlo f6 6sample buffer (360 mM Tris-HCl [pH 6.7], 60%
glycerol and 12% SDS), which was supplemented immediately
prior to use with 150 mlo fb-mercaptoethanol and 150 mlo fa
saturated bromophenol blue solution per 2.5 ml. Next, the
samples were heated for 5 min at 100uC and subjected to
electrophoresis through an SDS-10% polyacrylamide gel. Re-
solved proteins were subsequently transferred onto an Immobilon-
P membrane (Millipore) by electroblotting. After incubation for
2 h at room temperature (RT) with blocking solution (10 mM
Tris-HCl [pH 8.0], 150 mM NaCl and 0.05% Tween-20 [TBST])
containing 10% non-fat dry milk powder (Elk, Campina), the
Western blot was incubated overnight at 4uC with monoclonal
antibody 303.9 diluted 1:50 in blocking solution. Next, the
Immobilon membrane was washed 3 times for 5 min each with
TBST at RT and subjected to a 1-h incubation with horseradish
peroxidase-conjugated goat-anti-mouse IgG secondary antibodies
(Santa Cruz Biotechnoloy; catalog number: sc-2005) diluted
1:10,000 in blocking solution. After three 20-min washes with
TBST, the Western blot was incubated for 5 min with
chemiluminescence substrate solution (100 mM Tris-HCl
[pH 8.6], 250 mg/ml 5-amino-2,3-dihydro-1,4-phthalazinedione
[Sigma-Aldrich]) which was supplemented immediately prior to
use with 20 ml of a 30% H2O2 solution and 1 ml of a 0.33% 3-(4-
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dimethylsulfoxide per 100 ml. The chemiluminescent signal was
visualized by exposing the Immobilon membrane to an Amersham
Hyperfilm MP film. Actin served as loading control and was
detected by using a 1:5,000 dilution of a mouse monoclonal
antibody (clone: C4; MP Biomedicals; catalog number: 691001).
Chromosomal DNA extraction and analysis
The purification of chromosomal DNA was carried essentially
as previously described [49] except for the use of a different lysis
buffer consisting of 100 mM Tris-HCl (pH 8.5), 5 mM EDTA
(pH 8.0), 0.2% SDS and 200 mM NaCl. After restriction enzyme
digestion with Eco32I (Fermentas) and electrophoresis through
0.8% agarose gels in 16Tris-acetate-EDTA buffer, the DNA was
transferred by capillary action onto Amersham Hybond-XL
membranes. These membranes were subsequently incubated with
blocking solution, exposed to the DNA probes specified below and
repeatedly washed using a standard Southern hybridization
procedure. Next, the Southern blots were exposed to autoradiog-
raphy films. Before incubating the nylon membranes with new
probes, the previous probes were removed by soaking them in a
boiling 0.1% SDS solution. After cooling to RT the 0.1% SDS
solution was discarded and the procedure was repeated twice.
The AAVS1-specific probe (353 bp) was obtained by PCR
amplification using the template, primer pair and cycling
parameters described elsewhere [14]. The 377-bp probe covering
the AAV p5 promoter and rbG gene pA signal was also generated
by PCR using construct pAd/AAV.EGFP [14] as template and
the oligodeoxyribonucleotides 59-GTCCATTCCTTATTCCA-
TAGAAAAGC-39 plus 59-CCATCGATTGGAGTCGTGAC-
GTGAATTACGTCATAGGGTTAGGGAGGTCCTGTATTA-
GAGGTCACG-39,whereas the eGFP-specific probe (596 bp) was
PCR amplified from plasmid pEGFP-N1 (Clontech) with the aid
of the primers 59-GAGCTGGACGGCGACGTAAACG-39 and
59-CGCTTCTCGTTGGGGTCTTTGCT-39. The final concen-
trations of template, primers (Invitrogen), dNTPs (Fermentas) and
GoTaq polymerase (Promega) in the 50-ml PCR mixtures were
20 pg/ml, 0.2 mM, 0.2 mM and 50 mU/ml, respectively. All PCR-
derived probes as well as the 1.9-kb human dystrophin cDNA-
specific Eco32I fragment used as an internal vector probe were
purified by agarose gel electrophoresis followed by gel extraction
using the QIAEX II system (Qiagen) according to the instructions
provided by the manufacturer. Prior to their addition to the
hybridization solution, the radiolabeled DNA probes were
separated from unincorporated dNTPs through size-exclusion
chromatography by using Sephadex-50 (GE Healthcare) columns.
PCR-based targeted DNA integration assay
Four hundred thousand DMD myoblasts were seeded in wells of
24-well plates. After overnight incubation, the cells were infected
with dHV.68/5939.F50 alone (40 HTUs/cell) or were co-infected
with dHV.68/5939.F50 (40 HTUs/cell) and hcAd.FLPe.F50
(40 GSAUs/cell). The cells were exposed to the viral vectors for
24 hours after which the inocula were substituted by fresh culture
medium. At 72 hours postinfection, genomic DNA was extracted
from these cells as described above. Chromosomal DNA was also
extracted from HeLa cell clone N+2 and DMD myoblast clone
3C5, which were derived from cells stably transduced with
dHV.68/5939.F50 DNA through random and AAVS1-targeted
DNA insertion, respectively. Next, samples containing 160 ng of
genomic DNA were subjected to PCR with the AAVS1-specific
primer # 211 (59-CAGGTCCACCCTCTGCTG-39), together
with primer # 651 (59-TTCCTAACCCCAACACTTGC-39)
targeting the vector DNA (i.e. hEF1a promoter sequence). PCR
amplifications with the AAVS1-specific oligodeoxyribonucleotides
# 211 and # 196 (59-GGCTCAACATCGGAAGAGG-39) were
carried out in parallel to serve as a control for template integrity
and are expected to give rise to a 354-bp PCR product. PCR
mixtures of 50 ml containing 200 mM dNTPs, 0.2 mM of each
primer, 0.012 U/ml of Phusion High-Fidelity DNA polymerase
(Finnzymes) and 16GC buffer (Finnzymes) were placed in a DNA
Engine Tetrad 2 thermal cycler (Bio-Rad) and a touchdown PCR
program was initiated by a 3-min incubation at 98uC, followed by
19 cycles of 98uC for 20 sec, an annealing period of 30 sec with
the temperature decreasing by 0.5uC every cycle from 62 to 52uC,
and a 2-min extension step at 72uC. When the PCR program
reached the lower annealing temperature of 52uC, 28 additional
cycles were performed by using the same cycling conditions except
for the use of a constant annealing temperature of 52uC. This was
followed by a 5-min incubation at 72uC. Next, 1 ml of each PCR
sample was subjected to a nested PCR with the AAVS1- and vector
DNA-specific primers #212 (59-GCTTTGCCACCCTATGCT-
GAC-39) and # 188 (59-GGATCTGAGGAACCCCTAGT-
GATGG-39), respectively. The cycling conditions applied to the
nested PCR were as described above except for the use of a
maximal annealing temperature of 69uC and a final touchdown
temperature of 59uC. Samples from all PCR amplifications were
subjected to agarose gel electrophoresis. Subsequently, PCR
products were purified from the gel with the aid of the JetSorb
gel extraction kit (GENOMED) and the recovered DNA was
inserted into cloning vector pCR-Blunt II-TOPO (Invitrogen)
according to the instructions supplied by the manufacturers.
Finally, the nucleotide sequence of several of the cloned PCR
fragments was determined as previously described [45] by using
the M13 forward (59-GACGTTGTAAAACGACGGCCAGT-39)
or reverse (59-CAGGAAACAGCTATGACCATGA-39) primer.
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